

Irene Cacciola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1303178/publications.pdf>

Version: 2024-02-01

82
papers

3,669
citations

331538

21
h-index

155592

55
g-index

83
all docs

83
docs citations

83
times ranked

4063
citing authors

#	ARTICLE	IF	CITATIONS
1	Occult Hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver Disease. <i>New England Journal of Medicine</i> , 1999, 341, 22-26.	13.9	651
2	Occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2007, 46, 160-170.	1.8	458
3	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. <i>Gastroenterology</i> , 2004, 126, 102-110.	0.6	389
4	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
5	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	0.6	291
6	Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications. <i>Journal of Hepatology</i> , 2014, 61, 408-417.	1.8	208
7	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	1.8	138
8	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695.	1.9	124
9	Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. <i>Cancer</i> , 2006, 106, 1326-1330.	2.0	118
10	Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. <i>Hepatology</i> , 1997, 26, 495-499.	3.6	115
11	Replicative and Transcriptional Activities of Hepatitis B Virus in Patients Coinfected with Hepatitis B and Hepatitis Delta Viruses. <i>Journal of Virology</i> , 2011, 85, 432-439.	1.5	88
12	Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 696-700.	1.8	88
13	Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. <i>Hepatology</i> , 2000, 31, 507-512.	3.6	69
14	The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. <i>Liver International</i> , 2017, 37, 71-79.	1.9	57
15	Long-term response to interferon alpha is unrelated to interferon sensitivity determining regional variability in patients with chronic hepatitis C virus-1b infection. <i>Journal of Hepatology</i> , 1999, 30, 1023-1027.	1.8	52
16	Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. <i>Journal of Hepatology</i> , 2002, 36, 426-432.	1.8	49
17	Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. <i>American Journal of Gastroenterology</i> , 2002, 97, 1518-1523.	0.2	44
18	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , 2019, 114, 1275-1282.	0.2	41

#	ARTICLE	IF	CITATIONS
19	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	1.8	38
20	Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. <i>Journal of Hepatology</i> , 2004, 40, 515-519.	1.8	37
21	TT virus has a ubiquitous diffusion in human body tissues: analyses of paired serum and tissue samples. <i>Journal of Viral Hepatitis</i> , 2003, 10, 95-102.	1.0	28
22	Atrial fibrillation in patients with cirrhosis. <i>Liver International</i> , 2016, 36, 395-400.	1.9	17
23	Erectile dysfunction in compensated liver cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 843-849.	0.4	17
24	Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care. <i>Internal and Emergency Medicine</i> , 2017, 12, 181-186.	1.0	16
25	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
26	Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. <i>Digestive and Liver Disease</i> , 2011, 43, 996-1000.	0.4	14
27	New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress. <i>Medicina (Lithuania)</i> , 2022, 58, 530.	0.8	12
28	Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography. <i>Medicine (United States)</i> , 2016, 95, e4836.	0.4	11
29	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199.	1.0	11
30	Elective endoscopic variceal ligation is not a risk factor for bacterial infection in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 366-369.	0.4	10
31	Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the "ANSWER" study. <i>Journal of Hepatology</i> , 2017, 66, S93.	1.8	9
32	Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. <i>Liver International</i> , 2018, 38, 1220-1229.	1.9	9
33	Behaviour of Occult HBV Infection in HCV-Infected Patients under Treatment with Direct-Acting Antivirals. <i>Antiviral Therapy</i> , 2019, 24, 187-192.	0.6	9
34	Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 333-337.	1.0	9
35	Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. <i>Liver International</i> , 2021, 41, 2059-2067.	1.9	9
36	Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study.. <i>Liver International</i> , 2005, 25, 555-563.	1.9	8

#	ARTICLE	IF	CITATIONS
37	Fibroscan: a new noninvasive method for evaluation of liver dysfunction in Turner syndrome. <i>European Journal of Clinical Investigation</i> , 2011, 41, 183-188.	1.7	8
38	Lack of the NS5B S282T Mutation in HCV Isolates from Liver Tissue of Treatment-Naive Patients with HCV Genotype-1b Infection. <i>Antiviral Therapy</i> , 2015, 20, 245-247.	0.6	8
39	Fever and rhomboid target lesion in decompensated cirrhosis. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 576.	4.6	7
40	Mucocutaneous toxicity during simeprevir treatment for hepatitis C. A single institution, retrospective case series. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1152-1154.	1.1	6
41	Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort. <i>Journal of Hepatology</i> , 2018, 68, S83.	1.8	6
42	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017, 49, e60.	0.4	5
43	Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. <i>Digestive and Liver Disease</i> , 2018, 50, 1-2.	0.4	4
44	Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. <i>Digestive and Liver Disease</i> , 2015, 47, e6.	0.4	3
45	Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 66, S23-S24.	1.8	3
46	Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. <i>Internal and Emergency Medicine</i> , 2022, 17, 1609-1616.	1.0	3
47	Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry. <i>Digestive and Liver Disease</i> , 2017, 49, e6.	0.4	2
48	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017, 49, e59.	0.4	2
49	Real-time PCR quantification of serum and intracellular HBV DNA and HDV RNA in different subsets of chronic HBV infected individuals. <i>Digestive and Liver Disease</i> , 2009, 41, A20-A21.	0.4	1
50	577 REAL-TIME PCR QUANTIFICATION OF SERUM AND INTRACELLULAR HBV DNA AND HDV RNA IN DIFFERENT SUBSETS OF CHRONIC HBV INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S212.	1.8	1
51	Corrigendum to: "Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C" [<i>J Hepatol</i> 2013;59:696-700]. <i>Journal of Hepatology</i> , 2014, 60, 238.	1.8	1
52	Frailty index is a strong predictor of in-hospital outcomes and mortality after discharge in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2017, 49, e57.	0.4	1
53	Non-invasive tools to ruling out large varices: RESIST-HCV vs. Baveno VI criteria in a large cohort of patients with HCV cirrhosis. <i>Journal of Hepatology</i> , 2017, 66, S563.	1.8	1
54	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. <i>Journal of Hepatology</i> , 2019, 70, e234-e235.	1.8	1

#	ARTICLE	IF	CITATIONS
55	PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT. <i>Digestive and Liver Disease</i> , 2019, 51, e75-e76.	0.4	1
56	Effects of Proton Pump Inhibitors in Cirrhotic Patients: What Do We Really Know?. <i>Gastroenterology</i> , 2022, 163, 47-49.	0.6	1
57	Virological profiles in patients with chronic hepatitis C and "apparent" or "occult" HBV infection. <i>Journal of Hepatology</i> , 2000, 32, 92.	1.8	0
58	Molecular analyses of TT virus in paired serum and tissue samples from 150 patients with either hepatic or non-hepatic disease. <i>Journal of Hepatology</i> , 2002, 36, 92.	1.8	0
59	6 EPIDEMIOLOGICAL CHANGES OF BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: A CURRENT CLINICAL PROBLEM. <i>Digestive and Liver Disease</i> , 2010, 42, S3.	0.4	0
60	Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography. <i>Digestive and Liver Disease</i> , 2015, 47, e17.	0.4	0
61	SP211 ACUTE KIDNEY INJURY IN CIRRHOTIC PATIENTS UNDERGOING CONTRAST-ENHANCED COMPUTED TOMOGRAPHY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii448-iii448.	0.4	0
62	Hepatitis C Treatment with First-Generation Protease Inhibitors in A Real-World Cohort: Risk-Benefit Profile and Costs of the Therapy. <i>Value in Health</i> , 2016, 19, A511.	0.1	0
63	Clinical outcome in hospitalized cirrhotic patients with bacterial infections treated with empirical or antibiogram-guided therapy. <i>Digestive and Liver Disease</i> , 2016, 48, e44-e45.	0.4	0
64	Erectile dysfunction in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, e36.	0.4	0
65	Clinical Outcome in Hospitalized Cirrhotic Patients with Bacterial Infections Treated with Empirical or Antibiogram-Guided Therapy. <i>Journal of Hepatology</i> , 2016, 64, S261-S262.	1.8	0
66	NS3 Genetic Variability in HCV Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C. <i>Journal of Hepatology</i> , 2016, 64, S403.	1.8	0
67	Evaluation of Prevalence of Erectile Dysfunction and Associated Risk Factors in Patients with Liver Cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, S286.	1.8	0
68	NS3 genetic variability in HCV genotype 1a isolates from liver tissues and serum samples of treatment-naïve patients with chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2016, 48, e35-e36.	0.4	0
69	Efficacy of early empiric antibiotic treatment and its impact on short-term mortality in cirrhotic patients with subsequent identification of the infecting bacteria. <i>Digestive and Liver Disease</i> , 2017, 49, e58.	0.4	0
70	Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals. <i>Journal of Hepatology</i> , 2017, 66, S218.	1.8	0
71	Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, e17.	0.4	0
72	Bacterial infection is an uncommon occurrence in cirrhotic patients undergoing endoscopic variceal ligation. <i>Digestive and Liver Disease</i> , 2017, 49, e57.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirrhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry. <i>Journal of Hepatology</i> , 2017, 66, S510-S511.	1.8	0
74	P.05.17: The Course of Inflammatory Bowel Disease in Patients Under Treatment with Direct Antiviral Agents for Hepatitis C – A preliminary Report. <i>Digestive and Liver Disease</i> , 2017, 49, e163.	0.4	0
75	The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance. <i>Digestive and Liver Disease</i> , 2018, 50, 20.	0.4	0
76	NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C. <i>Intervirolgy</i> , 2018, 61, 1-8.	1.2	0
77	OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS. <i>Digestive and Liver Disease</i> , 2019, 51, e94.	0.4	0
78	Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort. <i>Digestive and Liver Disease</i> , 2019, 51, e262-e263.	0.4	0
79	Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy. <i>Digestive and Liver Disease</i> , 2019, 51, e16-e17.	0.4	0
80	Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules. <i>Internal and Emergency Medicine</i> , 2021, 16, 949-955.	1.0	0
81	Cirrhotic Patients with Bacterial Infection and Negative Cultures Have a More Advanced Disease and an Increased Short-Term Mortality Rate. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	0
82	Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease. <i>Annals of Hepatology</i> , 2021, , 100578.	0.6	0